FilingSEC EDGAR6-K
Innate Pharma announces effectiveness of Sobi partnership and initiation of Phase 3 trial
· SEC accepted
StagePartnership effective and trial initiation
Filing content
The strategic partnership with Sobi is now effective following the completion of closing conditions, triggering a $75 million upfront payment and the initiation of the TELLOMAK-3 Phase 3 study.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…